Here is the design of a clinical trial:

Official Title: THE PEBBLES STUDY: A Randomised Controlled Trial to Prevent Eczema, Food Allergy and Sensitisation Using a Skin Barrier Improvement Strategy

Included conditions:
- Eczema
- Asthma
- Allergy;Food

Study Armgroups:
- {'label': 'Twice daily use treatment with EpiCeram', 'type': 'ACTIVE_COMPARATOR', 'description': 'They will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for 6 months. The prophylactic use of EpiCeram™ is the intervention that is being tested for its effect on infant skin barrier function. We will instruct parents to apply approximately 6 grams of EpiCeram™ per application at two regular times each day, including after bathing the infant, or at the time they would normally bathe their child.', 'interventionNames': ['Drug: EpiCeram']}
- {'label': 'Standard skin care', 'type': 'NO_INTERVENTION', 'description': 'Parents are to follow standard skin care practices'}

Interventions:
- {'type': 'DRUG', 'name': 'EpiCeram', 'description': 'Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.', 'armGroupLabels': ['Twice daily use treatment with EpiCeram']}

Primary Outcomes:
- {'measure': 'Presence of eczema', 'description': 'as assessed using i) the UK working party criteria for eczema and/or ii) blinded investigator observed eczema.', 'timeFrame': '12 months of age.'}
- {'measure': 'Confirmed diagnosis of food allergy at 12 months (52 weeks).', 'description': "This diagnosis is derived from a combination of allergic sensitisation, reaction history and food challenge. A skin prick test to six common allergens will be performed (egg white, cows' milk, peanut, dust mite, cat dander, and rye grass) along with a negative (saline) and a positive (histamine) control. Participants that are sensitised to certain foods (\\>=1mm wheal) during the skin prick testing will be given a challenge to determine if they are allergic to those foods. This will be conducted at the MCRI Allergy Clinic under the supervision of a Doctor specifically trained in oral food challenges.", 'timeFrame': '12 months of age'}

Please estimate the sample size based on the assumption: 
The study assumes 86% power for the AD outcome and 80% power for the food allergy outcome. Additionally, there is an expectation of up to 80% loss to follow-up for participants with FLG null mutations.
Sample size
        We require 760 participants (380 in each group). With 380 infants per group, we will have, (1)Â 86% power to demonstrate that the intervention causes an absolute risk reduction for AD of 12% (from 40% to 28%, RR=0.7), and (2)Â 80% power to detect a 7.5% reduction in food allergy at 12 months (from 15% to 7.5%, RR=0.5). As the population prevalence of FLG null mutations is approximately 10%,33 and we will only recruit children with a family history of allergic disease, we expect at least 15% of participants to have one or more FLG null mutation. This will result in 45 infants per group (allowing for up to 80% loss to follow-up) with one or more such mutations. We will have approximately 80% power to detect a relative risk of 0.40 (20% vs 50%) induced by the treatment for the outcome of AD.